Reference | Patient demographics: | Description of matched pairs | Synchronous/metachronous/metastases, n:n | Molecular marker assessment technique | Mutation frequency,c n/N (%) | Concordance, n/N (%) | |||
---|---|---|---|---|---|---|---|---|---|
(i) Median age (range), years | N | Tumour sample storage form | Primary | Metastatic: n | |||||
(ii) Gender, n/N (%) male | Histological subtype: n | Time between primary and metastatic tumour sample collection b | |||||||
(iii) Ethnicity [countrya] | |||||||||
(iv) Smoking status, n/N (%) | |||||||||
Assessment of EGFR molecular marker | |||||||||
Chen et al. [27] | (i) 58 (27–84) | 180 | Archived | Lung | Lymph node: 49 | 40:140 | High-resolution melting method | 119/235 (51) vs lymph node metastases 15/49 (31); | [Overall] |
(ii) 112/180 (62.2) | Pulmonary nodules: 41 | N/A | pulmonary nodules 19/41 (46); | 155/180 (86) | |||||
(iii) Asian | Chest wall: 15 | distant metastatic tumours 16/35 (46) | [Paired pulmonary primary nodules] | ||||||
(iv) Never-smoker: 52/180 (28.9); ever-smoker: 128/180 (71.1) | Pleural: 8 | 31/41 (76) | |||||||
Brain: 5 | [Paired primary lung tumours and distant metastases] | ||||||||
Liver: 3 | 30/35 (86) | ||||||||
Adrenal gland: 3 | [Paired primary lung tumours and metastatic lymph nodes] | ||||||||
Retroperitoneal lymph node: 1 | 44/49 (90) | ||||||||
[Paired metachronous primary tumours] | |||||||||
50/55 (91) | |||||||||
Gow et al. [28] | (i) 61 (38–80) | 67 | FFPE | Lung | Brain: 25 | N/A | Direct sequencing and ARMS method | [Direct sequencing] | [Direct sequencing] |
(ii) 40/67 (60) | Bone: 20 | Median time between resection of primary and corresponding metastatic tumours: 9.3 months (range: 0–90) | 18/67 (27) vs 26/67 (39) | 41/67 (61) | |||||
(iii) [Taiwan] | Pleura/skin/soft tissue: 11 | [Direct sequencing and ARMS method combined] | |||||||
(iv) Never-smoker: 41/67 (61); ever-smoker: 26/67 (39) | Distant lymph node: 4 | 49/67 (73) | |||||||
Gastrointestinal system: 4 | |||||||||
Metastatic lung: 2 | |||||||||
Adrenal gland: 1 | |||||||||
Luo et al. [54] | (i) 55 (26–79) at diagnosis | 15 | FFPE | Lung | Brain | N/A | ARMS method | 7/15 (47) vs 8/15 (53) | 14/15 (93) |
(ii) 83/136 (61) | N/A | ||||||||
(iii) [China] | |||||||||
(iv) Never-smoker: 73/136 (53.7); ever-smoker: 51/136 (37.5) | |||||||||
Mansuet-Lupo et al. [30] | (i) N/A | 10 | FFPE | Lung | Lymph node: 8 | N/A | ‘Locally validated tests’ | N/A | 10/10 (100) |
(ii) N/A | ADC: 10 | Pleura: 2 | N/A | ||||||
(iii) Caucasian [France] | |||||||||
(iv) N/A | |||||||||
Matsumoto et al. [53] | (i) N/A (43–70) | 8 | N/A | Lung | Brain | N/A | Direct sequencing (after laser capture microdissection in some cases) | 6/8 (75) vs 6/8 (75) | 8/8 (100) |
(ii) 5/8 (63) | Time between resection of primary and corresponding metastatic tumours (range): 0.5–64 months | ||||||||
(iii) [Japan] | |||||||||
(iv) Never-smoker: 3/8 (38); ever-smoker: 5/8 (63) | |||||||||
Park et al. [31] | (i) 61 (32–82) | 101 | FFPE | Lung | Lymph node | 101:0 | Direct sequencing and heteroduplex analysis | [Direct sequencing] | [Direct sequencing] |
(ii) 73/101 (72.3) | [Concurrent] | 21/101 (21) vs 11/101 (11) | 89/101 (88) | ||||||
(iii) [Korea] | [Heteroduplex analysis] | [Heteroduplex analysis] | |||||||
(iv) Never-smoker: 29/101 (28.7); ever-smoker: 66/101 (65.4) | 29/101 (29) vs 26/101 (26) | 84/101 (83) | |||||||
Shimizu et al. [52] | (i) [Mean] 69.1 (37–83) | 70 | Paraffin embedded | Lung | Lymph node | N/A | PNA-LNA PCR clamp method | 21/70 (30) vs 11/70 (16) | 60/70 (86) |
(ii) 46/70 (66) | ADC: 35 | [Concurrent] | |||||||
(iii) [Japan] | SSC: 24 | ||||||||
(iv) Never-smoker: 22/70 (31.4); ever-smoker: 48/70 (68.6) | ADQCC: 5 | ||||||||
LCC: 4 | |||||||||
Pleomorphic carcinoma: 2 | |||||||||
Tang et al. [60] | (i) N/A | 9d | FFPE | Lung | Lymph node: 9 | N/A | Direct sequencing following laser-capture microdissection | 54/56 (96) vs 25/30 (83) | N/A |
(ii) N/A | ADC: 9 | N/A | |||||||
(iii) [USA] | |||||||||
(iv) N/A | |||||||||
Wei et al. [50] | (i) [38/50 > 60 years; 12/50 ≤ 60 years] | 50 | FFPE | Lung | Lymph node | N/A | Real-time fluorescent PCR | 50/50 (100) vs 47/50 (94) | (47/50) 94 |
(ii) 11/50 (N/A) | ADC: 49 | N/A | |||||||
(iii) Chinese | SSC: 1 | ||||||||
(iv) Never-smoker: 40/50 (N/A); ever-smoker: 10/50 (N/A) | |||||||||
Yatabe et al. [51] | (i) N/A | 77 | Fresh frozen | Lung | Lymph node | N/A | Direct sequencing | 77/77 (100) vs 77/77 (100) | (77/77) 100 |
(ii) N/A | N/A | ||||||||
(iii) [Japan] | |||||||||
(iv) N/A |